Survivin Long Peptide Vaccine (SurVaxM) in Metastatic NETs

Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors

CLINICALTRIALS.GOV IDENTIFIER: NCT03879694

Drug/Treatment: SVN53-67/M57-KLH peptide vaccine (SurVaxM) and octreotide acetate (Sandostatin LAR)

PHASE: 1

STATUS: Recruiting

Sponsor: Roswell Park Cancer Institute

Collaborator: NeuroEndocrine Tumor Research Foundation (NETRF)

Dr. Heloisa Soares Discusses Survivin Long Peptide Vaccine in Metastatic NETs

DESCRIPTION:

This phase I trial studies the side effects of survivin long peptide vaccine and how it works with the immune system in treating patients with neuroendocrine tumors that have spread to other parts of the body (metastatic). Tumor cells make proteins that are not usually produced by normal cells. The body sees these proteins as not belonging and sends white blood cells called T cells to attack the tumor cells that contain these proteins. By vaccinating with small pieces of these proteins called peptides, the immune system can be made to kill tumor cells. Giving survivin long peptide vaccine to patients who have survivin expression in their tumors may create an immune response in the blood that is directed against neuroendocrine tumors.

For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here.

CONTACT/Principal Investigator:

Renuka V. Iyer, MD

EMAIL: Renuka.Iyer@roswellpark.org

PHONE: 716-845-2300